bacterium that causes syphilis), and Haemophilus ducreyi (a gram-negative bacteria that causes chancroid). Although chancroid has not been reported in Australia since 1998, the total number of Australian notifications of syphilis have ranged from 1304 notifications in 1997 to 2056 in 2004 [21] . An additional but rare cause of GUD is the gramnegative organism traditionally entitled Calymmatobacterium granulomatis. Further characterization of the organism by cell culture [8, 14] and DNA sequencing resulted in the proposed reclassification of the organism to Klebsiella granulomatis [5, 9] . The disease has been commonly known as granuloma inguinale, but the preferred name, donovanosis, is less limiting when de-scribing the potential of the disease to affect many anatomical sites, resulting in chronic, ulcerative disease [4] . Although it is generally a benign infection, disease can result in extensive tissue destruction and can even be fatal [13] . Donovanosis is endemic in parts of Southern Africa, Brazil, India, Papua New Guinea, the Caribbean, and Central and Northern Australia, including the north of Western Australia [13, 22] . Despite that the number of Australian donovanosis notifications decreased from 117 in 1994 to 16 in 2002 and 2003 [21] , clinical underdiagnosis of the condition, in addition to the reluctance of persons to present for treatment, is suspected of falsely depressing prevalence figures [3, 16] . The detection of donovan bodies within large mononuclear cells obtained in smears of lesion or biopsy material remains the conclusive diagnostic approach, requiring careful specimen selection and expert histological investigation [13] .
PCR has improved the speed and sensitivity of microbial diagnosis and permitted more-common use of less invasive sampling techniques [6, 23] . Multiplex PCR makes best use of limited amounts of clinical material when multiple targets are under investigation, and it improves cost-effectiveness [27] . C. (Klebsiella) granulomatis has not been included in previously reported multiplex PCR assays investigating GUD, despite the existence of a robust PCR technique [7, 10] .
We report the first single-tube, multiplex PCR to simultaneously detect 5 microbial agents of GUD together with an endogenous internal control included to determine any effects on amplification caused by inhibitors or degraded template. This collaborative project was undertaken to address the need for a rapid, economical, and sensitive approach to the detection and diagnosis of treatable GUD using noninvasive sampling techniques. The intent of the application of the genital ulcer disease multiplex PCR (GUMP) assay was also to improve understanding of the prevalence of donovanosis in at-risk populations and test the hypothesis that Queensland is chancroid free.
METHODS AND MATERIALS
Clinical specimens. To perform a prospective study of the multiplex PCR, 64 specimens consisting of smear and/or press slides ( ), swabs ( ), and tissue biopsies ( ) n p 3 n p 59 n p 2 were collected. The specimens, as part of routine clinical care, were supplied without detailed clinical histories, but it is known that they were collected from 55 HIV-uninfected subjects (58.9% of whom were male) presenting at remote area health centers in northern Queensland with any acute or chronic genital lesion during 2002. Subjects were not excluded on the basis of previous or ongoing antimicrobial therapy. The subject population predominantly comprised Aborigines and Torres Strait Islanders who ranged in age from 2.6 years to 59.4 years, with a median age of 24.8 years. Results were compared with those of conventional testing, including PCR, bacterial and viral culture, histologic analysis, rapid plasmin reagin (RPR) and Venereal Disease Research Laboratory assays, T. pallidum particle agglutination (TPPA), and fluorescent treponemal antibody absorption. Nucleic acids were purified from 200 mL of each resuspended specimen using the High Pure PCR Template Preparation Kit (Roche Diagnostics).
PCR. Multiplex PCR combined 5 mL of synthetic control or purified specimen with 45 mL of PCR mix (4 mM of MgCl 2 ; 50 mM of KCl; 10 mM of Tris-HCl [pH, 8.3] ; 0.2 mM of dATP, dCTP, and dGTP; 0.4 mM of dUTP; and 3 mM of digoxigenin-11-dUTP [Boehringer Mannheim]) containing 2 pmol of each oligonucleotide primer (Sigma-Genosys) (table 1) and 2 units of PlatinumTaq DNA polymerase (Invitrogen). The primers for HSV, H. ducreyi and T. pallidum were chosen from a previous study [23] , whereas the primers for C. granulomatis were unique to this study. Amplification commenced with a 2-min incubation at 95ЊC followed by 45 cycles of 20 s at 94ЊC, 20 s at 62ЊC, and 30 s at 72ЊC and a final 7-min incubation at 72ЊC.
Uniplex PCR containing template DNA was performed as described for multiplex PCR, except only a single primer pair corresponding to 1 target sequence was included. Confirmatory PCR assays were employed for discrepant results for HSV and T. pallidum by targeting the polymerase and 16S rRNA genes, respectively [18, 26] .
Amplicon was detected by agarose gel electrophoresis or by enzyme linked amplicon hybridization assay (ELAHA), a microwell DNA hybridization method using an enzyme-mediated color reaction to indicate the presence of specific template amplification [19] .
Construction of synthetic controls. Positive controls containing cloned templates were assembled for each target, as described elsewhere [19] . Templates were obtained from clinical material. Each primer pair's amplicon was electrophoresed, purified (QIAquick gel extraction kit; Qiagen), and ligated into the pGEM-T Easy Vector System I (Promega). Plasmids containing the insert were transformed into Escherichia coli DH5a and expanded in culture, and 1 mL of the transformed bacteria was directly screened by PCR-ELAHA. Positive clones were purified using a mini-prep purification kit (GenElute Plasmid Miniprep Kit; Sigma). The controls were designated pWCtpal (T. pallidum subspecies pallidum), pWCcg (C. granulomatis), pWChsv1, pWChsv2, pWChd (H. ducreyi), and pWCerv (endogenous retrovirus 3).
Synthetic control stocks were initially quantified at 260 nm using a UV visible spectrometer (Cintra 20; GBC) then titrated using 10-fold dilutions from 10 7 to 10 0 copies/mL. Each dilution was tested by uniplex PCR to confirm the expected copy number, as described elsewhere [18] . Quantified stock solutions containing adjusted copy numbers in the range of to 9 1 ϫ 10 amplifiable targets were stored in 2-mL single-use ali- 9 5 ϫ 10 quots at Ϫ70ЊC. 1 Forward (01.X) and reverse (02.X) primers. 2 Oligonucleotide probe is identified by the "P" preceding the 3 digit identification number.
C. (Klebsiella) granulomatis confirmation. Confirmation of C. granulomatis among Klebsiella-positive specimens was performed by digesting the amplicon with 5 units of HaeIII (Promega) in a total volume of 20 mL (figure 1).
Further confirmation of the presence of C. granulomatis required amplification of the 16S rRNA gene using primers 16S rRNA 01.1 and 02.1 (table 1) [9] . Both strands of amplicon representing ∼500 bases proximal to the 5 end of the gene were sequenced (ABI PRISM BigDye v3.1; Perkin Elmer Applied Biosystems Division).
RESULTS
Analytical sensitivity and assay specificity. ELAHA increased the limit of amplicon detection by at least 8-fold, compared with agarose gel electrophoresis of an equal amount of amplicon (data not shown) [18] . GUMP-ELAHA was capable of detecting copies of each synthetic control template per 0 3 ϫ 10 50-mL reaction, or, when all 6 templates, including the internal control, were coamplified, GUMP-ELAHA was capable of detecting copies per reaction (table 2) . In addition, all 1 3 ϫ 10 coamplified template loads above the limit of detection could be visualized using agarose gel electrophoresis and discriminated by ELAHA (data not shown , and human genomic DNA (Promega). The only GUMP primer pair to crossreact with an unintended template was that for the detection of C. granulomatis, which amplified some enterobacterial non-GUMP targets.
The GUMP study. A GUMP target was identified in 22 specimens (34.3%), comprising 4 HSV specimens (6.2%) and 18 T. pallidum specimens (28.1%), whereas 42 (65.6%) of the 64 specimens remained negative for a target by GUMP-ELAHA (table 3) . Twenty specimens (31.2%) were negative for a target by both GUMP-ELAHA and traditional testing. There were 4 instances in which HSV-2 was detected by culture but not by Figure 1 . The expected restriction enzyme patterns resulting from HaeIII restriction of the 328-base pair (bp) phosphate porin (phoE) amplicon generated by amplification of Klebsiella templates using genital ulcer disease multiplex polymerase chain reaction (primer sites are boxed). The 167-bp fragment (A) was diagnostic for Calymmatobacterium granulomatis and was absent when unintended bacterial species were amplified and restricted. B, The Klebsiella rhinoscleromatis sequence is presented as an example of a nontarget species of Klebsiella. GUMP-ELAHA: in 1 instance, HSV-2 was detected by the confirmatory assay; in another instance, detection was affected by amplification failure; and in the remaining 2 instances, the specimens originated from the same subject and repeatedly tested negative by both HSV assays. To further examine the performance of the HSV component of GUMP-ELAHA, 103 previously determined HSV-positive and HSV-negative swab specimens (50 were HSV negative, 24 were HSV-1 positive, 26 were HSV-2 positive, and 3 were dual HSV positive) were examined, and the results demonstrated that the HSV component of GUMP-ELAHA was capable of an analytical sensitivity of 98.2% and a specificity of 96.1%. No subjects were found to be positive for either H. ducreyi or C. granulomatis. Of the 11 subjects who were negative for T. pallidum by the GUMP-ELAHA assay but positive for antibody elicited by treponemal infection, 8 had previous clinical diagnoses of syphilis. Accounting for the new information increased the sensitivity and specificity values of the T. pallidum component (table 3; values are in square brackets). No previous results or relevant clinical histories were available for the remaining 4 subjects. No dual infections were detected among the GUMP targets; however, a total of 8 subjects contained indications of 2 microbes in their specimens. Three subjects were positive for Chlamydia trachomatis and T. pallidum; 2 subjects were positive for C. trachomatis and Neisseria gonorrhoeae; 2 subjects were positive for T. pallidum and HSV-2; and 1 subject was positive for T. pallidum and N. gonorrhoeae. In all but 3 (5.0%) of the subject specimens tested, the endogenous internal control template was amplifiable. Clinically, the failure of the endogenous internal control only affected the diagnostic outcome of 2 (3.3%) of the study specimens, because one of the endogenous retrovirus-negative samples was positive for a pathogen.
C. (Klebsiella) granulomatis confirmatory assays. The C. granulomatis PCR primers yielded a 328 base pair amplicon from C. granulomatis and other Klebsiella species, including K. pneumoniae, K. oxytoca species, and K. planticola, and from some E. coli strains. Discrimination of these from true C. granulomatis templates was achieved by generating a diagnostic 167-base pair fragment following restriction of the amplicon with HaeIII ( figure 2 ). No C. granulomatis was detected during the prospective study period; however, ongoing use of GUMP detected C. granulomatis in 1 instance during 2004 and in 2 instances during 2005 from clinically diagnosed subjects. DNA sequencing of a fragment of the 16S rRNA gene of the 3 strains confirmed that they shared 100% of their nucleotide sequence identities. Their nearest homologues were C. granulomatis (99.5% identity) and Klebsiella rhinoscleromatis (99.3% identity). Phylogenetic analysis confirmed these associations, dem- onstrating branching patterns similar to those described elsewhere (figure 3) [5, 9] .
DISCUSSION
The GUMP assay was developed to detect sexually transmitted ulcerating agents among at-risk Australian populations, with a view to expediting the eradication of these diseases from Australia. The assay is currently in restricted use in Northern Queensland, which resulted in 3 instances in which C. granulomatis was detected, confirming that donovanosis remains in some parts of Australia. The lack of H. ducreyi detections suggest that chancroid is uncommon among our subjects; however, testing a larger specimen population will be required to translate this suggestion to the broader target community.
GUMP-ELAHA proved to be sensitive, even when all 5 microbial templates were coamplified; however, it is extremely unlikely that this would occur in a clinical environment. Our expanded assay retained identical analytical sensitivity to the multiplex PCR described by Orle et al. [23] , on which GUMP-ELAHA was founded. Primers used in the assay used by Orle and colleagues were further validated by use in India, Thailand, and Lesotho [1, 20, 24] . The improvements to sensitivity and specificity brokered by the ELAHA satisfactorily balanced the addition of primers to detect C. granulomatis and an endogenous retrovirus-3 target serving as an endogenous internal control. Additionally, because GUMP is capable of codetecting a range of templates at a range of concentrations from a single reaction, it follows that clinical samples that are strongly positive for a single microbial template do not require further investigation to ensure that competitive PCR conditions have not masked the amplification of a second or third target.
Our study included, for the first time in a multiplex PCR assay to detect agents of GUD, an endogenous internal control to monitor template quality and purification efficiency. Amplification failure occurred for 5.0% of all specimens. This was similar to previous reports of diagnostic PCR failure [2, 11, 17, 25, 28] . Nonetheless, only 3% of the field trial results were adversely affected, which was less than that reported by Orle et al. [23] , and we assumed that PCR inhibition or template degradation was the cause of these failures. Additional specimens were not available to permit re-extraction of endogenous internal control-negative material. The analyses of sensitivity and specificity data for the T. pallidum component of the assay were affected by the nature of the conventional testing methods and a paucity of detailed clinical histories. Lesion swabs were the specimen type of choice for the GUMP assay to detect microbes at the site of infection; however, traditional testing for syphilis principally relied on serological assays, which detect a nonspecific immune response to recent, previous, and systemic treponemal infection.
The T. pallidum primers theoretically amplify other members of the T. pallidum species, because of their genetic similarities; however, the nonvenereal disease associated with these other treponemes is uncommon in Australia and generally responds to the therapies used to treat syphilis. The C. granulomatis component of the multiplex PCR was the source of the only proven unintended amplification observed during use of GUMP-ELAHA. Nonetheless, restriction-enzyme digestion and nucleotide sequencing adequately discriminated between C. granulomatis and genetically similar bacteria. Diagnostic amplification of C. granulomatis DNA by PCR was first described in an article in 1999 by Carter et al. [7] , in which the phoE (phosphate porin) gene was targeted . This assay was complemented by nucleotide sequencing to identify 2 unique base Figure 2 . Agarose gel electrophoresis of Klebsiella species and suspected Calymmatobacterium granulomatis amplicon before and after HaeIII restriction digestion. Lane 1, 100-base pair (bp) DNA molecular weight marker; lanes 2 and 3, Escherichia coli amplicon following and preceding restriction digestion, respectively; lanes 4 and 5, Klebsiella pneumoniae amplicon following and preceding restriction digestion, respectively; lanes 6 and 7, Calymmatobacterium granulomatis amplicon following and preceding restriction digestion, respectively. changes in C. granulomatis that eliminated HaeIII restriction sites and differentiated this bacterium from other members of the Enterobacteriaceae family. Whereas Carter et al. [7, 10] used known positive biopsy samples to validate PCR sensitivity, together with a small number of genital swabs obtained from patients with other conditions to check specificity, we applied a synthetic control and examined DNA from numerous related microorganisms to extend the assay validation data, particularly for H. ducreyi and C. granulomatis, for which limited positive clinical material was available. Limited sequence data is publicly available for C. granulomatis strains; therefore, future studies should aim to sequence the phoE target to ensure the stability of the nucleotide polymorphism over time and around the world. Should the mutation prove to be a reliable target, a realtime PCR assay capable of discriminating the polymorphism should prove to be a useful and significantly more rapid diagnostic tool. Three suspected clinical cases of donovanosis were confirmed by GUMP-ELAHA and by restriction, indicating that the relevant polymorphism remains stable in Australia. Phylogenetic analysis of 16S rRNA gene sequencing indicated that the 3 Australian strains were most closely related to C. granulomatis. Restriction of the amplicon proved to be the most rapid confirmatory assay, whereas nucleotide sequencing was not essential for routine confirmation.
The GUMP study detected the presence of a target microbe in 34% of specimens provided to our laboratory. By comparison, traditional PCR, culture, and serological testing were able to identify at least 1 pathogen in 67% of specimens (64% of patients). Other studies report that more than one-third of specimens have negative results in multiplex PCR studies; however, the etiology of GUD in different study regions may vary dramatically, making comparison with our population difficult [6, 20, 24] . The disparity between GUMP-ELAHA and traditional results can be largely explained by the inclusion C. trachomatis and N. gonorrhoeae PCR and culture testing, in addition to the use of traditional serological assays that overdiagnosed T. pallidum infections; indeed, on retrospective analysis of the available diagnostic data, it was found that some subjects in this study had been previously diagnosed with syphilis. It is likely that these circulating antibodies contributed to ). Accession numbers for sequences obtained from GenBank are shown. n p 1000 a positive serodiagnosis, despite the absence of treponemes at the lesion site, as indicated by a negative GUMP result. Similar problems have been reported by Orle et al. [20] , who proposed that treponemal serologic testing could lead to overdiagnosis of primary syphilis, reflecting its insensitive and nonspecific nature. The sensitivity and rapidity of GUMP-ELAHA could prove that it is especially useful for early identification of primary syphilis, whereas indirect RPR, fluorescent treponemal antibody absorption, TPPA, and Venereal Disease Research Laboratory assays can take weeks to be of diagnostic value. Similarly, Chen et al. [12] demonstrated no concordance between H. ducreyi serologic testing and PCR. Because GUMP-ELAHA was intended to detect microbial nucleic acids at the site of an active lesion, similar to the function of fluorescent microscopy, detailed comparison of the PCR with serological treponemal testing is largely unwarranted. However, the role of serological assays is important, because they provide an indication of the history of treponemal infection among persons with previous exposure; thus, serologic testing should continue to be used in conjunction with GUMP-ELAHA. We believe that the number of diagnoses could be further increased if complete clinical histories were available to address the relatively low number of HSV detections in our study. An unidentifiable number of the study subjects were suffering from recurring or persistent GUD and had been tested previously for HSV and subsequently prescribed treatment. Therefore, the overall likelihood that HSV could be detected among the GUMP study population was reduced, compared with other studies. A separate validation of the HSV component of GUMP-ELAHA demonstrated high sensitivity and specificity, reinforcing that presampling therapies could have been responsible for the reduced number of HSV detections. The GUMP population contained a total of 8 codetections; however, the severity of disease associated with suspected multiple infections could not be inferred from the data.
We have described a single-tube multiplex PCR assay to diagnose common and rare causes of GUD. GUMP performed with high sensitivity and was more rapid and more objective than conventional assays, including culture and fluorescent antibody techniques, for the direct detection of all targets. Additional applications of GUMP-ELAHA would benefit from a longer-term study of the role of PCR versus traditional testing among a larger and better-defined study population. Nonetheless, decreased turnaround times for results should permit earlier and more appropriate treatment of disease, whereas the less invasive nature of the sampling techniques should encourage more subjects to present for diagnosis of ulcerated lesions, thus improving our understanding of the epidemiology of these diseases and helping us to focus our efforts to eradicate them.
